Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02715804 · ClinicalTrials.gov registry record · Phase 3
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
A Phase 3 study, sponsored by Halozyme Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 492
- Enrollment target
NCT02715804 is a Phase 3 study that was terminated before completion, run by Halozyme Therapeutics. The registered enrollment target is 492 participants.
The verdict
NCT02715804, a Phase 3 study, was terminated before completion, sponsored by Halozyme Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 492 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA).
Interventions
- DRUG Placebo
- DRUG Gemcitabine
- DRUG nab-Paclitaxel
- OTHER Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2016-03-14 |
| Est. Completion | 2019-11-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02715804
The ClinicalTrials.gov registry entry for NCT02715804 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 492 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Halozyme Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02715804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02715804 about?
NCT02715804 is a clinical study titled "A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma". The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in participants with hyaluronan (H...
What is the current status of trial NCT02715804?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 492 participants. The study started on 2016-03-14. Estimated completion is 2019-11-04.
What interventions are being tested in trial NCT02715804?
The interventions under investigation include: Placebo (DRUG), Gemcitabine (DRUG), nab-Paclitaxel (DRUG), Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20) (OTHER).
Who is sponsoring clinical trial NCT02715804?
This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.